Theratechnologies (NASDAQ:THTX) Issues Quarterly Earnings Results

Theratechnologies (NASDAQ:THTX) announced its quarterly earnings results on Tuesday. The company reported ($0.10) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.07) by ($0.03), Fidelity Earnings reports. Theratechnologies had a negative net margin of 37.10% and a negative return on equity of 112.84%. During the same quarter in the previous year, the firm posted ($0.09) EPS.

Shares of NASDAQ THTX opened at $3.57 on Thursday. The company has a current ratio of 2.41, a quick ratio of 1.74 and a debt-to-equity ratio of 1.52. Theratechnologies has a 12 month low of $1.83 and a 12 month high of $4.46. The firm has a market capitalization of $338.13 million, a PE ratio of -11.90 and a beta of 1.65. The firm has a fifty day simple moving average of $3.61 and a two-hundred day simple moving average of $3.63.

A hedge fund recently raised its stake in Theratechnologies stock. Morgan Stanley increased its holdings in Theratechnologies Inc. (NASDAQ:THTX) by 143.9% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,716,512 shares of the company’s stock after acquiring an additional 1,012,777 shares during the quarter. Morgan Stanley owned about 1.81% of Theratechnologies worth $6,660,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 19.29% of the stock is currently owned by institutional investors and hedge funds.

Several equities research analysts have weighed in on the stock. Zacks Investment Research raised shares of Theratechnologies from a “sell” rating to a “hold” rating in a research report on Wednesday, September 15th. Canaccord Genuity cut shares of Theratechnologies from a “buy” rating to a “hold” rating and dropped their price target for the company from $8.00 to $3.00 in a research report on Thursday, July 29th. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat, Theratechnologies has a consensus rating of “Hold” and a consensus price target of $3.17.

About Theratechnologies

Theratechnologies, Inc is a pharmaceutical company. It engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). The firm offers its product under the brand name of EGRIFTA, which approved therapy for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.

Further Reading: The risks of owning bonds

Earnings History for Theratechnologies (NASDAQ:THTX)

Receive News & Ratings for Theratechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies and related companies with's FREE daily email newsletter.